# Syndax Pharmaceuticals Inc: financial statements, quarterly

SNDX · Nasdaq · CIK 1395937 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sndx.md) · [Financials](/companies/sndx/financials.md) · [Filings](/companies/sndx/filings.md) · [Insiders](/companies/sndx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sndx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-121439.md) | [0.0 d](/filings/0001193125-26-076536.md) | [0.0](/filings/0000950170-25-063518.md) | [3.5](/filings/0000950170-25-101985.md) | [12.5](/filings/0001193125-25-262521.md) | [7.7 d](/filings/0001193125-26-076536.md) | [20.0](/filings/0001193125-26-197154.md) | [38.0](/filings/0001193125-26-332750.md) | [45.9](/filings/0001193125-25-262521.md) | [68.7 d](/filings/0001193125-26-076536.md) | [64.9](/filings/0001193125-26-197154.md) | [72.8](/filings/0001193125-26-332750.md) |
| Research and development | $m | [39.1](/filings/0000950170-24-121439.md) | [55.1 d](/filings/0001193125-26-076536.md) | [56.5](/filings/0000950170-25-063518.md) | [48.7](/filings/0000950170-25-101985.md) | [71.0](/filings/0001193125-25-262521.md) | [65.5 d](/filings/0001193125-26-076536.md) | [61.6](/filings/0001193125-26-197154.md) | [62.2](/filings/0001193125-26-332750.md) | [56.3](/filings/0001193125-25-262521.md) | [78.6 d](/filings/0001193125-26-076536.md) | [58.8](/filings/0001193125-26-197154.md) | [68.0](/filings/0001193125-26-332750.md) |
| Operating income | $m | [(56.4)](/filings/0000950170-24-121439.md) | [(77.9) d](/filings/0001193125-26-076536.md) | [(79.5)](/filings/0000950170-25-063518.md) | [(74.2)](/filings/0000950170-25-101985.md) | [(89.6)](/filings/0001193125-25-262521.md) | [(96.4) d](/filings/0001193125-26-076536.md) | [(83.8)](/filings/0001193125-26-197154.md) | [(69.4)](/filings/0001193125-26-332750.md) | [(57.4)](/filings/0001193125-25-262521.md) | [(62.5) d](/filings/0001193125-26-076536.md) | [(34.2)](/filings/0001193125-26-197154.md) | [(40.0)](/filings/0001193125-26-332750.md) |
| Interest expense | $m | [0.1](/filings/0000950170-23-058165.md) | [0.1 d](/filings/0000950170-24-021253.md) | [0.1](/filings/0000950170-24-055053.md) | [0.0](/filings/0000950170-24-089241.md) | [0.0](/filings/0001193125-25-262521.md) | [(0.1) d](/filings/0001193125-26-076536.md) | [0.0](/filings/0001193125-26-197154.md) | [0.0](/filings/0001193125-26-332750.md) | [0.0](/filings/0001193125-25-262521.md) | [0.0 d](/filings/0001193125-26-076536.md) | [0.0](/filings/0001193125-26-197154.md) | [0.0](/filings/0001193125-26-332750.md) |
| Income tax | $m | not reported | not reported | [0.0](/filings/0000950170-25-063518.md) | [0.0 d](/filings/0000950170-25-101985.md) | [0.0 d](/filings/0001193125-25-262521.md) | not reported | [0.0](/filings/0001193125-26-197154.md) | [0.0 d](/filings/0001193125-26-332750.md) | [0.0 d](/filings/0001193125-25-262521.md) | [0.4 d](/filings/0001193125-26-076536.md) | [0.0](/filings/0001193125-26-197154.md) | [0.0 d](/filings/0001193125-26-332750.md) |
| Net income | $m | [(51.1)](/filings/0000950170-24-121439.md) | [(72.5) d](/filings/0001193125-26-076536.md) | [(72.4)](/filings/0001193125-25-262521.md) | [(68.1)](/filings/0001193125-25-262521.md) | [(84.1)](/filings/0001193125-25-262521.md) | [(94.2) d](/filings/0001193125-26-076536.md) | [(84.8)](/filings/0001193125-26-332750.md) | [(71.8)](/filings/0001193125-26-332750.md) | [(60.7)](/filings/0001193125-25-262521.md) | [(68.0) d](/filings/0001193125-26-076536.md) | [(42.7)](/filings/0001193125-26-332750.md) | [(49.4)](/filings/0001193125-26-332750.md) |
| Diluted EPS | $ per share | [(0.73)](/filings/0000950170-24-121439.md) | not reported | [(0.85)](/filings/0000950170-25-063518.md) | [(0.80)](/filings/0000950170-25-101985.md) | [(0.98)](/filings/0001193125-25-262521.md) | not reported | [(0.98)](/filings/0001193125-26-197154.md) | [(0.83)](/filings/0001193125-26-332750.md) | [(0.70)](/filings/0001193125-25-262521.md) | not reported | [(0.48)](/filings/0001193125-26-197154.md) | [(0.55)](/filings/0001193125-26-332750.md) |
| Basic EPS | $ per share | [(0.73)](/filings/0000950170-24-121439.md) | not reported | [(0.85)](/filings/0000950170-25-063518.md) | [(0.80)](/filings/0000950170-25-101985.md) | [(0.98)](/filings/0001193125-25-262521.md) | not reported | [(0.98)](/filings/0001193125-26-197154.md) | [(0.83)](/filings/0001193125-26-332750.md) | [(0.70)](/filings/0001193125-25-262521.md) | not reported | [(0.48)](/filings/0001193125-26-197154.md) | [(0.55)](/filings/0001193125-26-332750.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [94.6](/filings/0000950170-23-058165.md) | [295](/filings/0001193125-26-076536.md) | [115](/filings/0000950170-24-055053.md) | [105](/filings/0000950170-24-089241.md) | [133](/filings/0000950170-24-121439.md) | [154](/filings/0001193125-26-076536.md) | [154](/filings/0000950170-25-063518.md) | [109](/filings/0000950170-25-101985.md) | [117](/filings/0001193125-25-262521.md) | [135](/filings/0001193125-26-332750.md) | [131](/filings/0001193125-26-197154.md) | [336](/filings/0001193125-26-332750.md) |
| Current assets | $m | [381](/filings/0000950170-23-058165.md) | [581](/filings/0000950170-25-030394.md) | [454](/filings/0000950170-24-055053.md) | [446](/filings/0000950170-24-089241.md) | [415](/filings/0000950170-24-121439.md) | [603](/filings/0001193125-26-076536.md) | [549](/filings/0000950170-25-063518.md) | [532](/filings/0000950170-25-101985.md) | [530](/filings/0001193125-25-262521.md) | [528](/filings/0001193125-26-332750.md) | [471](/filings/0001193125-26-197154.md) | [675](/filings/0001193125-26-332750.md) |
| Total assets | $m | [399](/filings/0000950170-23-058165.md) | [613](/filings/0000950170-25-030394.md) | [543](/filings/0000950170-24-055053.md) | [477](/filings/0000950170-24-089241.md) | [426](/filings/0000950170-24-121439.md) | [725](/filings/0001193125-26-076536.md) | [641](/filings/0000950170-25-063518.md) | [596](/filings/0000950170-25-101985.md) | [552](/filings/0001193125-25-262521.md) | [530](/filings/0001193125-26-332750.md) | [473](/filings/0001193125-26-197154.md) | [704](/filings/0001193125-26-332750.md) |
| Current liabilities | $m | [39.2](/filings/0000950170-23-058165.md) | [58.1](/filings/0000950170-25-030394.md) | [50.8](/filings/0000950170-24-055053.md) | [42.5](/filings/0000950170-24-089241.md) | [59.4](/filings/0000950170-24-121439.md) | [104](/filings/0001193125-26-076536.md) | [94.6](/filings/0000950170-25-063518.md) | [113](/filings/0000950170-25-101985.md) | [114](/filings/0001193125-25-262521.md) | [120](/filings/0001193125-26-332750.md) | [86.2](/filings/0001193125-26-197154.md) | [99.7](/filings/0001193125-26-332750.md) |
| Total liabilities | $m | [40.0](/filings/0000950170-23-058165.md) | [58.7](/filings/0000950170-25-030394.md) | [51.1](/filings/0000950170-24-055053.md) | [42.6](/filings/0000950170-24-089241.md) | [59.4](/filings/0000950170-24-121439.md) | [437](/filings/0001193125-26-076536.md) | [426](/filings/0000950170-25-063518.md) | [439](/filings/0000950170-25-101985.md) | [436](/filings/0001193125-25-262521.md) | [465](/filings/0001193125-26-332750.md) | [431](/filings/0001193125-26-197154.md) | [689](/filings/0001193125-26-332750.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-030394.md) | not reported | not reported | not reported | [338](/filings/0001193125-26-076536.md) | [336](/filings/0000950170-25-063518.md) | [331](/filings/0000950170-25-101985.md) | [327](/filings/0001193125-25-262521.md) | [350](/filings/0001193125-26-332750.md) | [350](/filings/0001193125-26-197154.md) | [350](/filings/0001193125-26-332750.md) |
| Shareholders' equity | $m | [359](/filings/0000950170-24-121439.md) | [554](/filings/0001193125-26-076536.md) | [492](/filings/0001193125-25-262521.md) | [434](/filings/0001193125-25-262521.md) | [366](/filings/0001193125-25-262521.md) | [288](/filings/0001193125-26-332750.md) | [215](/filings/0001193125-26-332750.md) | [157](/filings/0001193125-26-332750.md) | [115](/filings/0001193125-25-262521.md) | [64.6](/filings/0001193125-26-332750.md) | [41.6](/filings/0001193125-26-332750.md) | [15.1](/filings/0001193125-26-332750.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(44.7) d](/filings/0000950170-24-121439.md) | [(41.3) d](/filings/0001193125-26-076536.md) | [(83.5)](/filings/0000950170-25-063518.md) | [(71.6) d](/filings/0000950170-25-101985.md) | [(62.3) d](/filings/0001193125-25-262521.md) | [(57.4) d](/filings/0001193125-26-076536.md) | [(95.2)](/filings/0001193125-26-197154.md) | [(87.8) d](/filings/0001193125-26-332750.md) | [(70.5) d](/filings/0001193125-25-262521.md) | [(69.5) d](/filings/0001193125-26-076536.md) | [(50.3)](/filings/0001193125-26-197154.md) | [(30.3) d](/filings/0001193125-26-332750.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [60.7](/filings/0000950170-23-058165.md) | [69.4](/filings/0000950170-24-055053.md) | [69.6](/filings/0000950170-24-089241.md) | [69.9](/filings/0000950170-24-121439.md) | [85.2](/filings/0000950170-25-063518.md) | [85.3](/filings/0000950170-25-101985.md) | [85.4](/filings/0001193125-25-262521.md) | [86.2](/filings/0001193125-26-197154.md) | [86.3](/filings/0001193125-26-332750.md) | [86.6](/filings/0001193125-25-262521.md) | [88.3](/filings/0001193125-26-197154.md) | [89.0](/filings/0001193125-26-332750.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 89,297,086 at 2026-07-31, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332750.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.